- Previous Close
45.62 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 49.38 - Volume
338 - Avg. Volume
113,264 - Market Cap (intraday)
45.595B - Beta (5Y Monthly) --
- PE Ratio (TTM)
18.50 - EPS (TTM)
2.46 - Earnings Date Nov 13, 2024
- Forward Dividend & Yield 0.58 (1.58%)
- Ex-Dividend Date Mar 22, 2023
- 1y Target Est
--
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
www.lundbeck.com5,600
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0ND5.IL
View MorePerformance Overview: 0ND5.IL
Trailing total returns as of 10/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0ND5.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0ND5.IL
View MoreValuation Measures
Market Cap
43.34B
Enterprise Value
41.33B
Trailing P/E
17.48
Forward P/E
14.49
PEG Ratio (5yr expected)
6.30
Price/Sales (ttm)
2.19
Price/Book (mrq)
1.95
Enterprise Value/Revenue
2.00
Enterprise Value/EBITDA
12.69
Financial Highlights
Profitability and Income Statement
Profit Margin
12.79%
Return on Assets (ttm)
5.62%
Return on Equity (ttm)
12.04%
Revenue (ttm)
19.38B
Net Income Avi to Common (ttm)
2.48B
Diluted EPS (ttm)
2.46
Balance Sheet and Cash Flow
Total Cash (mrq)
3.66B
Total Debt/Equity (mrq)
22.91%
Levered Free Cash Flow (ttm)
1.97B